Video
Author(s):
Neal D. Shore, MD, discusses what’s on the horizon with PARP inhibitors in the treatment paradigm for patients with prostate cancer. Shore is medical director for the Carolina Urologic Research Center and chief medical officer, Surgical Oncology and Urology, for Genesis Care (US).
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.